Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Quince Therapeutics, Inc. (QNCX) had Normalized Income after Taxes of $-13.44M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-13.44M |
|
-- |
|
-- |
|
$13.43M |
|
$-13.43M |
|
$-0.06M |
|
$-13.49M |
|
$-13.49M |
|
$-13.44M |
|
$-13.44M |
|
$-13.44M |
|
|
Normalized Income after Taxes |
$-13.44M |
$-13.43M |
|
$-13.63M |
|
53.95M |
|
53.95M |
|
$-0.25 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$29.20M |
|
$0.62M |
|
$80.70M |
|
$109.90M |
|
$26.04M |
|
-- |
|
$82.80M |
|
$108.84M |
|
$1.06M |
|
$-66.67M |
|
$1.06M |
|
54.49M |
|
| Cash Flow Statement Financials | |
$-30.94M |
|
$15.16M |
|
$15.88M |
|
$6.21M |
|
$6.45M |
|
$0.24M |
|
$3.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.12 |
|
-- |
|
-- |
|
-- |
|
16.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-31.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1269.36% |
|
20.16% |
|
-12.23% |
|
-1269.31% |
|
$0.02 |
|
$-0.58 |
|
$-0.57 |
|